GlassScriptPhysician profile
Ravi J Patel
NPI 1750607354
$5,603.87
in general payments reported to CMS, 2019-2025
31 companies · $853 in 2025
The $853 reported for 2025 was more than what a typical Gastroenterology (Internal Medicine) provider received nationally (typical 2025 total: $636).
See the full distribution for Gastroenterology (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $261 · 2020: $581 · 2021: $1,226 · 2022: $845 · 2023: $1,013 · 2024: $825 · 2025: $853.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,691.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,690.66 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $2,007.71 | 2019-2025 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $493.88 | 2019-2025 | Xifaxan |
| Gilead Sciences, INC. | $384.42 | 2019-2025 | |
| Janssen Biotech, INC. | $312.53 | 2019-2025 | Tremfya, Stelara, Simponi |
| Boston Scientific Corporation | $293.32 | 2020-2024 | Exalt Model D, Watchman Flx |
| Takeda Pharmaceuticals U.S.A., INC. | $250.90 | 2021-2025 | Entyvio, Gattex, Eohilia |
| Pfizer INC. | $219.27 | 2021-2025 | |
| Mauna Kea Technologies, INC. | $162.19 | 2020-2024 | |
| Genzyme Corporation | $147.03 | 2022-2024 | |
| Celgene Corporation | $138.97 | 2023-2024 | Zeposia |
| Nestle Healthcare Nutrition INC. | $135.39 | 2021-2022 | |
| Echosens North America, INC. | $121.28 | 2019 | |
| Bard Peripheral Vascular, INC. | $116.07 | 2022 | |
| Covidien LP | $97.38 | 2020 | |
| Braintree Laboratories, INC. | $92.92 | 2020-2022 |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $92.39 | 2021-2025 | Avsola, Amjevita |
| Regeneron Healthcare Solutions, INC. | $88.79 | 2022-2025 | Dupixent |
| Organon LLC | $86.61 | 2023-2025 | Hadlima, Nexplanon, Renflexis |
| Madrigal Pharmaceuticals | $79.42 | 2024-2025 | Resmetirom, Rezdiffra |
| Ironwood Pharmaceuticals, INC | $67.21 | 2020-2021 | |
| Ferring Pharmaceuticals INC. | $58.35 | 2020-2023 | Rebyota |
| Johnson & Johnson Surgical Vision, INC. | $48.92 | 2025 | Tecnis Simplicity |
| Medtronic, INC. | $19.79 | 2022 | |
| Alnylam Pharmaceuticals INC. | $19.73 | 2022 | |
| Lilly USA, LLC | $18.88 | 2023 | |
| Intercept Pharmaceuticals, INC. | $18.27 | 2020 | |
| Shionogi INC | $18.19 | 2019 | |
| Amag Pharmaceuticals, INC. | $14.06 | 2021 |
3 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ravi Patel listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.